薬理と治療

Abstract

Patients with neurodegenerative parkinsonian diseases often take medications for constipation. Thus far, few studies have investigated the association between the regular use of constipation medications and the use of dopaminergic medication in patients with neurodegenerative parkinsonian diseases. In addition, no reports have classified constipation medications according to the mechanism of action and evaluated the levodopa equivalent dose（LED）. This study analyzed 163 patients with neurodegenerative parkinsonian diseases who had been taking levodopa at the time of admission to the Department of Neurology, Fukuoka University Hospital from January 2016 to December 2018. Patients who regularly used constipation medications were defined as constipation medication users. Ninety-two patients （56.4％）who had neurodegenerative parkinsonian diseases regularly used constipation medications. The regular use of constipation medications was associated with the number of medications taken（odds ratio 1.292, 95％ confidence interval 1.121︱1.490）. The LED of neurodegenerative parkinsonian disease patients who regularly used stimulant laxatives was significantly higher in comparison to those who did not regularly use constipation medications（P＜0.05）. Further studies should be performed to investigate whether stimulant laxatives affect the absorption of therapeutic agents due to hypofunction of the intestinal tract.